Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ELTX Elicio Therapeutics

未开盘 12-29 16:00:00 EST

8.00

-0.07

-0.87%

盘后8.00

+0.000.00%

16:10 EST

最高8.07	最低7.80	成交量10.65万
今开8.07	昨收8.07	日振幅3.35%
总市值1.40亿	流通市值9,445万	总股本1,749万
成交额84.61万	换手率0.90%	流通股本1,181万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ELTX","market":"US","secType":"STK","nameCN":"Elicio Therapeutics","latestPrice":8,"timestamp":1767042000000,"preClose":8.07,"halted":0,"volume":106460,"hourTrading":{"tag":"盘后","latestPrice":8,"preClose":8,"latestTime":"16:10 EST","volume":185,"amount":1480,"timestamp":1767042603921},"delay":0,"floatShares":11806099,"shares":17489516,"eps":-3.088325,"marketStatus":"未开盘","change":-0.07,"latestTime":"12-29 16:00:00 EST","open":8.07,"high":8.07,"low":7.8,"amount":846119.91358,"amplitude":0.033457,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.088325,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1767085200000},"marketStatusCode":0,"adr":0,"listingDate":1612501200000,"exchange":"NASDAQ","adjPreClose":8.07,"preHourTrading":{"tag":"盘前","latestPrice":8.1,"preClose":8.07,"latestTime":"09:26 EST","volume":319,"amount":2583.9,"timestamp":1767018362374},"postHourTrading":{"tag":"盘后","latestPrice":8,"preClose":8,"latestTime":"16:10 EST","volume":185,"amount":1480,"timestamp":1767042603921},"volumeRatio":1.39781,"impliedVol":2.2249,"impliedVolPercentile":0.904},"requestUrl":"/m/hq/s/ELTX","defaultTab":"news","newsList":[{"id":"1126433588","title":"Elicio Therapeutics报告在进行中的第2阶段Amplify-7P试验中，抗原传播扩展至患者特异性新抗原超越Mkras","url":"https://stock-news.laohu8.com/highlight/detail?id=1126433588","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1126433588?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:05","pubTimestamp":1765458343,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics报告在进行中的第2阶段Amplify-7P试验中，抗原传播扩展至患者特异性新抗原超越Mkras","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ELTX"],"gpt_icon":0},{"id":"1197733595","title":"Elicio Therapeutics在SITC会议上报告Eli-002 7P的强效细胞毒性Mkras特异性T细胞反应及Eli-004的新预临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1197733595","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197733595?lang=zh_cn&edition=full","pubTime":"2025-11-07 22:01","pubTimestamp":1762524077,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics在关于其Eli-002 7P的第二阶段Amplify-7P试验的最新进展中，报告了跨多种患者HLA的强效细胞毒性Mkras特异性T细胞反应，以及Eli-004的最新预临床数据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ELTX","BK4007","BK4139"],"gpt_icon":0},{"id":"1135361685","title":"Elicio Therapeutics在进行中的第二阶段Amplify-7P试验中报告了多样HLA背景下强大的T细胞反应","url":"https://stock-news.laohu8.com/highlight/detail?id=1135361685","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135361685?lang=zh_cn&edition=full","pubTime":"2025-10-27 20:03","pubTimestamp":1761566580,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics在进行中的第二阶段Amplify-7P试验中报告了多样HLA背景下强大的T细胞反应","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ELTX","BK4007"],"gpt_icon":0},{"id":"1175575666","title":"Elicio Therapeutics宣布Eli-002 7P在正在进行的2期Amplify-7P试验中，99%的可评估患者产生了强劲的Mkras特异性T细胞反应","url":"https://stock-news.laohu8.com/highlight/detail?id=1175575666","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175575666?lang=zh_cn&edition=full","pubTime":"2025-09-17 20:01","pubTimestamp":1758110496,"startTime":"0","endTime":"0","summary":"Elicio Therapeutics宣布Eli-002 7P在正在进行的2期Amplify-7P试验中，99%的可评估患者产生了强劲的Mkras特异性T细胞反应","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ELTX"],"gpt_icon":0},{"id":"2516065459","title":"Elicio Therapeutics, Inc.盘中异动 快速下挫6.02%报7.81美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516065459","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516065459?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:08","pubTimestamp":1741025317,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时08分，Elicio Therapeutics, Inc.股票出现异动，股价大幅跳水6.02%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.18%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304020837abe6733b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304020837abe6733b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","BK4139","ELTX"],"gpt_icon":0},{"id":"2516379751","title":"Elicio Therapeutics, Inc.盘中异动 早盘大幅拉升5.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516379751?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:10","pubTimestamp":1740755402,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日23时10分，Elicio Therapeutics, Inc.股票出现异动，股价快速上涨5.68%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228231002a2580afc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250228231002a2580afc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","ELTX","BK4139"],"gpt_icon":0},{"id":"2514018228","title":"Elicio Therapeutics, Inc.盘中异动 急速上涨7.89%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514018228","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514018228?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:57","pubTimestamp":1740495451,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时57分，Elicio Therapeutics, Inc.股票出现波动，股价大幅上涨7.89%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.07%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225225731abdc8476&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225225731abdc8476&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","ELTX","BK4139"],"gpt_icon":0},{"id":"2513477855","title":"Elicio Therapeutics, Inc.盘中异动 早盘股价大跌5.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513477855","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513477855?lang=zh_cn&edition=full","pubTime":"2025-02-24 23:15","pubTimestamp":1740410110,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日23时15分，Elicio Therapeutics, Inc.股票出现异动，股价急速下跌5.21%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.46%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022423151198910089&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022423151198910089&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","LENZ","ELTX","BK4007"],"gpt_icon":0},{"id":"2513629117","title":"Elicio Therapeutics, Inc.盘中异动 股价大涨6.79%报8.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513629117","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513629117?lang=zh_cn&edition=full","pubTime":"2025-02-21 23:09","pubTimestamp":1740150582,"startTime":"0","endTime":"0","summary":"北京时间2025年02月21日23时09分，Elicio Therapeutics, Inc.股票出现异动，股价快速拉升6.79%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.14%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221230942988de732&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250221230942988de732&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","ELTX","BK4139"],"gpt_icon":0},{"id":"2511461563","title":"Elicio Therapeutics, Inc.盘中异动 大幅拉升5.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511461563","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511461563?lang=zh_cn&edition=full","pubTime":"2025-02-15 02:14","pubTimestamp":1739556867,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日02时14分，Elicio Therapeutics, Inc.股票出现波动，股价大幅上涨5.33%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.54%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021502142896234e44&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025021502142896234e44&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELTX","LENZ","BK4007","BK4139"],"gpt_icon":0},{"id":"2510286325","title":"Elicio Therapeutics, Inc.盘中异动 早盘股价大涨6.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510286325","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510286325?lang=zh_cn&edition=full","pubTime":"2025-02-10 22:31","pubTimestamp":1739197902,"startTime":"0","endTime":"0","summary":"北京时间2025年02月10日22时31分，Elicio Therapeutics, Inc.股票出现波动，股价快速拉升6.58%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.38%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223142a240a1e4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250210223142a240a1e4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ELTX","BK4139","LENZ"],"gpt_icon":0},{"id":"2508869142","title":"Elicio Therapeutics, Inc.盘中异动 急速下挫7.09%报8.65美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2508869142","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508869142?lang=zh_cn&edition=full","pubTime":"2025-02-03 23:12","pubTimestamp":1738595549,"startTime":"0","endTime":"0","summary":"北京时间2025年02月03日23时12分，Elicio Therapeutics, Inc.股票出现波动，股价急速跳水7.09%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.62%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203231229987975c2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203231229987975c2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELTX","LENZ","BK4139","BK4007"],"gpt_icon":0},{"id":"2507034965","title":"Elicio Therapeutics, Inc.盘中异动 早盘快速下跌5.63%报8.89美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507034965","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507034965?lang=zh_cn&edition=full","pubTime":"2025-01-31 22:38","pubTimestamp":1738334306,"startTime":"0","endTime":"0","summary":"北京时间2025年01月31日22时38分，Elicio Therapeutics, Inc.股票出现波动，股价大幅下跌5.63%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.65%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131223826a23543af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250131223826a23543af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ELTX","LENZ","BK4007"],"gpt_icon":0},{"id":"2507353621","title":"Elicio Therapeutics, Inc.盘中异动 股价大跌15.98%报8.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2507353621","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507353621?lang=zh_cn&edition=full","pubTime":"2025-01-30 22:32","pubTimestamp":1738247527,"startTime":"0","endTime":"0","summary":"北京时间2025年01月30日22时32分，Elicio Therapeutics, Inc.股票出现异动，股价急速跳水15.98%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.28%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223207a2345521&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250130223207a2345521&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","LENZ","BK4139","ELTX"],"gpt_icon":0},{"id":"2506306278","title":"Elicio Therapeutics, Inc.盘中异动 急速上涨6.33%报8.23美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2506306278","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2506306278?lang=zh_cn&edition=full","pubTime":"2025-01-27 22:54","pubTimestamp":1737989696,"startTime":"0","endTime":"0","summary":"北京时间2025年01月27日22时54分，Elicio Therapeutics, Inc.股票出现异动，股价急速上涨6.33%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为1.14%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127225457abba64dc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250127225457abba64dc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","ELTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2505862503","title":"Elicio Therapeutics, Inc.盘中异动 快速拉升5.49%","url":"https://stock-news.laohu8.com/highlight/detail?id=2505862503","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505862503?lang=zh_cn&edition=full","pubTime":"2025-01-24 23:38","pubTimestamp":1737733106,"startTime":"0","endTime":"0","summary":"北京时间2025年01月24日23时38分，Elicio Therapeutics, Inc.股票出现异动，股价急速上涨5.49%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.45%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124233826abb75ea7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250124233826abb75ea7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4007","ELTX","BK4139"],"gpt_icon":0},{"id":"2505777648","title":"Elicio Therapeutics, Inc.盘中异动 急速上涨6.51%报6.87美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2505777648","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505777648?lang=zh_cn&edition=full","pubTime":"2025-01-23 03:19","pubTimestamp":1737573584,"startTime":"0","endTime":"0","summary":"北京时间2025年01月23日03时19分，Elicio Therapeutics, Inc.股票出现波动，股价快速上涨6.51%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.25%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123031944abb4dfd8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250123031944abb4dfd8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ELTX","BK4139","BK4007","LENZ"],"gpt_icon":0},{"id":"2503134507","title":"Elicio Therapeutics, Inc.盘中异动 急速拉升5.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503134507","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503134507?lang=zh_cn&edition=full","pubTime":"2025-01-15 01:54","pubTimestamp":1736877260,"startTime":"0","endTime":"0","summary":"北京时间2025年01月15日01时54分，Elicio Therapeutics, Inc.股票出现异动，股价大幅拉升5.12%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.64%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501150154209603a150&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501150154209603a150&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ELTX","LENZ","BK4007"],"gpt_icon":0},{"id":"2502867638","title":"Elicio Therapeutics, Inc.盘中异动 股价大涨5.11%报5.96美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502867638","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502867638?lang=zh_cn&edition=full","pubTime":"2025-01-10 22:48","pubTimestamp":1736520485,"startTime":"0","endTime":"0","summary":"北京时间2025年01月10日22时48分，Elicio Therapeutics, Inc.股票出现异动，股价急速上涨5.11%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.92%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102248059861ec9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202501102248059861ec9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ELTX","BK4139","BK4007"],"gpt_icon":0},{"id":"2502777551","title":"Elicio Therapeutics, Inc.盘中异动 早盘股价大涨6.14%报6.40美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2502777551","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2502777551?lang=zh_cn&edition=full","pubTime":"2025-01-08 23:33","pubTimestamp":1736350433,"startTime":"0","endTime":"0","summary":"北京时间2025年01月08日23时33分，Elicio Therapeutics, Inc.股票出现波动，股价快速拉升6.14%。Elicio Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.29%。Elicio Therapeutics, Inc.公司简介：Elicio Therapeutics Inc 是一家临床阶段的生物技术公司，致力于为治疗选择有限且结果不佳的患者开发癌症免疫疗法。Elicio 正在为一系列侵袭性癌症设计靶向淋巴结的 AMPlifiers、免疫调节剂、佐剂和疫苗。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108233353985f84e3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250108233353985f84e3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","ELTX","BK4007","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://elicio.com","stockEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":-0.1453},{"period":"3month","weight":-0.2687},{"period":"6month","weight":0.0191},{"period":"1year","weight":0.5534},{"period":"ytd","weight":0.5686}],"compareEarnings":[{"period":"1week","weight":0.0044},{"period":"1month","weight":0.0065},{"period":"3month","weight":0.0325},{"period":"6month","weight":0.1086},{"period":"1year","weight":0.156},{"period":"ytd","weight":0.1736}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Elicio Therapeutics Inc于1998年4月6日在特拉华州成立。该公司是一家临床阶段的生物技术公司，开发用于治疗癌症和疾病的新型免疫疗法管道。通过结合免疫学和免疫疗法方面的专业知识，Elicio正在设计研究性两亲（AMP）免疫疗法，旨在精确靶向并充分接合淋巴结。Elicio正在为一系列侵袭性癌症和传染病设计淋巴结靶向放大器、免疫调节剂、佐剂和疫苗。","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":0.04284},{"month":2,"riseRate":0,"avgChangeRate":-0.151757},{"month":3,"riseRate":0.6,"avgChangeRate":0.140266},{"month":4,"riseRate":0.4,"avgChangeRate":-0.061838},{"month":5,"riseRate":0.8,"avgChangeRate":0.223746},{"month":6,"riseRate":0.2,"avgChangeRate":-0.190319},{"month":7,"riseRate":0.6,"avgChangeRate":0.060027},{"month":8,"riseRate":0.4,"avgChangeRate":-0.06958},{"month":9,"riseRate":0.6,"avgChangeRate":0.034992},{"month":10,"riseRate":0.2,"avgChangeRate":-0.198973},{"month":11,"riseRate":0.4,"avgChangeRate":-0.034248},{"month":12,"riseRate":0.4,"avgChangeRate":-0.004898}],"exchange":"NASDAQ","name":"Elicio Therapeutics","nameEN":"Elicio Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Elicio Therapeutics(ELTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Elicio Therapeutics,ELTX,Elicio Therapeutics股票,Elicio Therapeutics股票老虎,Elicio Therapeutics股票老虎国际,Elicio Therapeutics行情,Elicio Therapeutics股票行情,Elicio Therapeutics股价,Elicio Therapeutics股市,Elicio Therapeutics股票价格,Elicio Therapeutics股票交易,Elicio Therapeutics股票购买,Elicio Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Elicio Therapeutics(ELTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Elicio Therapeutics(ELTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}